Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEC PLATT

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1871656363
CMS profile
312443
Location
SCHENECTODY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,235.08

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,235.08 75

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEC PLATT

NPI 1871656363 · CMS profile ID 312443

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SCHENECTODY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871656363?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEC PLATT, NPI 1871656363, CMS profile ID 312443. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871656363?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALEC PLATT, NPI 1871656363, CMS profile ID 312443. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871656363?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALEC PLATT, NPI 1871656363, CMS profile ID 312443, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1871656363?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $1,235.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.7506/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738606751 CMS
GlaxoSmithKline, LLC. $22.9705/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738523615 CMS
Philips Electronics North America Corporation $12.9404/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751355635 CMS
AstraZeneca Pharmaceuticals LP $18.3503/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735816543 CMS
PORTOLA PHARMACEUTICALS, LLC $12.3602/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725054213 CMS
Advanced Respiratory, Inc $21.5202/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751012725 CMS
GlaxoSmithKline, LLC. $16.2402/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738524349 CMS
Genentech USA, Inc. $15.9502/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742975893 CMS
Philips Electronics North America Corporation $19.1102/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751355601 CMS
AstraZeneca Pharmaceuticals LP $11.3302/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736155535 CMS
GlaxoSmithKline, LLC. $19.0102/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738726807 CMS
Regeneron Healthcare Solutions, Inc. $16.7402/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724446715 CMS
GlaxoSmithKline, LLC. $17.6301/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738829015 CMS
Philips Electronics North America Corporation $14.0001/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751355587 CMS
GlaxoSmithKline, LLC. $16.5201/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738525719 CMS
Janssen Pharmaceuticals, Inc $17.1201/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718948367 CMS
GlaxoSmithKline, LLC. $8.5701/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738523601 CMS
Janssen Pharmaceuticals, Inc $10.1101/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718948361 CMS
AstraZeneca Pharmaceuticals LP $11.6401/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735956579 CMS
GlaxoSmithKline, LLC. $4.3401/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738976023 CMS
Harmony Biosciences LLC $22.3001/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750462923 CMS
GENZYME CORPORATION $18.5301/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744205357 CMS
AstraZeneca Pharmaceuticals LP $39.0501/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736216233 CMS
Philips Electronics North America Corporation $12.5401/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751355589 CMS
Philips Electronics North America Corporation $4.4201/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751355597 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,414.40 86
PY2020 $1,235.08 75
PY2021 $801.52 45
PY2022 $248.20 14
PY2023 $1,179.44 47
PY2024 $1,594.39 69
PY2025 $1,361.44 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $251,135.47 139
PY2024 Principal investigator $99,566.23 48
PY2023 Principal investigator $89,618.05 19
PY2022 Principal investigator $17,757.26 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $2,064.00 12/23/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614553
Principal investigator 1 Alkermes, Inc. $1,867.00 12/23/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616675
Principal investigator 1 Alkermes, Inc. $4,856.00 12/23/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624706
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625471
Principal investigator 1 Alkermes, Inc. $330.00 12/10/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626250
Principal investigator 1 Alkermes, Inc. $112.80 12/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615609
Principal investigator 1 Alkermes, Inc. $71.60 12/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618495
Principal investigator 1 Alkermes, Inc. $132.50 12/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626684
Principal investigator 1 GlaxoSmithKline, LLC. $36,364.68 11/21/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192188149
Principal investigator 1 Alkermes, Inc. $636.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613453
Principal investigator 1 Alkermes, Inc. $272.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614549
Principal investigator 1 Alkermes, Inc. $3,202.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615387
Principal investigator 1 Alkermes, Inc. $709.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617517
Principal investigator 1 Alkermes, Inc. $709.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617723
Principal investigator 1 Alkermes, Inc. $2,012.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619891
Principal investigator 1 Alkermes, Inc. $1,954.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622489
Principal investigator 1 Alkermes, Inc. $709.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622677
Principal investigator 1 Alkermes, Inc. $4,095.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623152
Principal investigator 1 Alkermes, Inc. $5,945.00 11/19/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625874
Principal investigator 1 Alkermes, Inc. $6,667.00 10/10/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613457
Principal investigator 1 Alkermes, Inc. $1,879.00 10/10/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615019
Principal investigator 1 Alkermes, Inc. $330.00 10/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620986
Principal investigator 1 Alkermes, Inc. $6,555.00 10/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624708
Principal investigator 1 Alkermes, Inc. $4,120.00 10/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625381
Principal investigator 1 Alkermes, Inc. $54.72 10/02/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613481
Principal investigator 1 Alkermes, Inc. $38.82 10/02/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613920
Principal investigator 1 Alkermes, Inc. $19.41 10/02/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614362
Principal investigator 1 Alkermes, Inc. $82.08 10/02/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622285
Principal investigator 1 Alkermes, Inc. $13.68 10/02/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626272
Principal investigator 1 Alkermes, Inc. $330.00 09/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623070
Principal investigator 1 Alkermes, Inc. $272.00 09/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615745
Principal investigator 1 Alkermes, Inc. $1,985.00 09/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617871
Principal investigator 1 Alkermes, Inc. $272.00 09/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621530
Principal investigator 1 GlaxoSmithKline, LLC. $34,624.80 09/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192188154
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614939
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619311
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619563
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619565
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625980
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615101
Principal investigator 1 Alkermes, Inc. $1,089.00 08/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613792
Principal investigator 1 Alkermes, Inc. $2,005.00 08/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618363
Principal investigator 1 Alkermes, Inc. $330.00 08/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623558
Principal investigator 1 Alkermes, Inc. $1,947.00 08/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625315
Principal investigator 1 Alkermes, Inc. $37.40 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612899
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613617
Principal investigator 1 Alkermes, Inc. $21.40 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614080
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615521
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615933
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616107
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616215
Principal investigator 1 Alkermes, Inc. $37.24 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617009
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617279
Principal investigator 1 Alkermes, Inc. $145.60 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617649
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618377
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618659
Principal investigator 1 Alkermes, Inc. $16.08 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619025
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619093
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619323
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619503
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620075
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620648
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621560
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621764
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622561
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622852
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624162
Principal investigator 1 Alkermes, Inc. $6.65 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624252
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625812
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625932
Principal investigator 1 Alkermes, Inc. $179.90 06/18/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626190
Principal investigator 1 Alkermes, Inc. $731.00 06/11/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617147
Principal investigator 1 Alkermes, Inc. $638.00 06/11/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617761
Principal investigator 1 Alkermes, Inc. $272.00 06/11/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618245
Principal investigator 1 Alkermes, Inc. $638.00 06/11/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620610
Principal investigator 1 Alkermes, Inc. $272.00 06/11/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622083
Principal investigator 1 Alkermes, Inc. $272.00 06/11/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623850
Principal investigator 1 Alkermes, Inc. $126.00 06/08/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624738
Principal investigator 1 Alkermes, Inc. $14.89 06/07/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621226
Principal investigator 1 Alkermes, Inc. $28.63 06/07/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623174
Principal investigator 1 Alkermes, Inc. $6.90 06/07/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623650
Principal investigator 1 Alkermes, Inc. $133.99 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613071
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615465
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616139
Principal investigator 1 Alkermes, Inc. $15.61 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618223
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619773
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620658
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622511
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625271
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626348
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626562
Principal investigator 1 Alkermes, Inc. $5,198.00 05/15/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619435
Principal investigator 1 Alkermes, Inc. $668.29 05/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618587
Principal investigator 1 Alkermes, Inc. $1,994.00 05/07/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613489
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613123
Principal investigator 1 Alkermes, Inc. $1,196.53 04/22/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620640
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621056
Principal investigator 1 Alkermes, Inc. $2,065.00 04/21/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613930
Principal investigator 1 Alkermes, Inc. $6,057.00 04/21/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616295
Principal investigator 1 Alkermes, Inc. $1,835.00 04/21/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619679
Principal investigator 1 Alkermes, Inc. $2,065.00 04/21/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620371
Principal investigator 1 Alkermes, Inc. $4,766.00 04/21/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623844
Principal investigator 1 Alkermes, Inc. $119.36 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613834
Principal investigator 1 Alkermes, Inc. $113.34 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614973
Principal investigator 1 Alkermes, Inc. $259.54 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617287
Principal investigator 1 Alkermes, Inc. $56.85 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621788
Principal investigator 1 Alkermes, Inc. $228.53 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622629
Principal investigator 1 Alkermes, Inc. $52.48 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623362
Principal investigator 1 Alkermes, Inc. $82.08 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623576
Principal investigator 1 Alkermes, Inc. $77.64 04/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624004
Principal investigator 1 GlaxoSmithKline, LLC. $10,073.00 03/14/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192188146
Principal investigator 1 Alkermes, Inc. $1,835.00 03/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613427
Principal investigator 1 Alkermes, Inc. $3,934.00 03/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619127
Principal investigator 1 Alkermes, Inc. $2,013.00 03/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619613
Principal investigator 1 Alkermes, Inc. $115.65 03/03/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614178
Principal investigator 1 Alkermes, Inc. $1,770.00 02/28/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617497
Principal investigator 1 Alkermes, Inc. $1,770.00 02/28/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622870
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615879
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616951
Principal investigator 1 Alkermes, Inc. $70.40 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616967
Principal investigator 1 Alkermes, Inc. $22.50 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618733
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620393
Principal investigator 1 Alkermes, Inc. $218.45 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620812
Principal investigator 1 Alkermes, Inc. $4,629.00 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621166
Principal investigator 1 Alkermes, Inc. $16.00 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621632
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622101
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622982
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624782
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624979
Principal investigator 1 Alkermes, Inc. $1,922.00 02/12/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626624
Principal investigator 1 Alkermes, Inc. $272.00 01/17/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615999
Principal investigator 1 Alkermes, Inc. $638.00 01/17/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617101
Principal investigator 1 Alkermes, Inc. $3,203.00 01/17/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617685
Principal investigator 1 Alkermes, Inc. $3,934.00 01/17/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620964
Principal investigator 1 Alkermes, Inc. $2,013.00 01/17/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622225
Principal investigator 1 Alkermes, Inc. $5,912.00 01/17/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626224
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627104
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627182
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
RESPIRATORY SPECIALISTS
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627250